[Selection Criteria for Peritonectomy With Hyperthermic Intraoperative Chemotherapy (HIPEC) in Peritoneal Carcinomatosis]

Zentralbl Chir. 2008 Sep;133(5):468-72. doi: 10.1055/s-2008-1076973. Epub 2008 Oct 15.
[Article in German]

Abstract

Background: Cytoreductive peritonectomy with hyperthermic intraoperative chemotherapy (HIPEC) is an established therapy for patients with gastrointestinal, gynaecological metastasised peritoneal carcinomatosis as well as primary peritoneal carcinomatous tumours.

Methods: On the basis of a literature review and our personal experience, selection criteria for peritonectomy are discussed.

Results: Computed tomography (CT) scans and diagnostic laparoscopy are not sufficient for the diagnosis of peritoneal carcinomatosis. The combination of fluorodeoxyglucose positron emission tomography (FDG-PET) and CT seems to be the most reliable diagnostic imaging method. In our institution, all patients undergo PET / CT prior to peritonectomy.

Conclusion: The PET / CT scan may play an important role in forecasting the operability of patients with peritoneal carcinomatosis.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Carcinoma / diagnosis
  • Carcinoma / drug therapy
  • Carcinoma / surgery*
  • Chemotherapy, Cancer, Regional Perfusion*
  • Combined Modality Therapy
  • Female
  • Fluorodeoxyglucose F18
  • Gastrointestinal Neoplasms / diagnosis
  • Gastrointestinal Neoplasms / drug therapy
  • Gastrointestinal Neoplasms / surgery*
  • Genital Neoplasms, Female / diagnosis
  • Genital Neoplasms, Female / drug therapy
  • Genital Neoplasms, Female / surgery*
  • Humans
  • Hyperthermia, Induced*
  • Laparoscopy
  • Patient Selection*
  • Peritoneal Neoplasms / diagnosis
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / secondary
  • Peritoneal Neoplasms / surgery*
  • Peritoneum / surgery*
  • Positron-Emission Tomography
  • Prognosis
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents
  • Fluorodeoxyglucose F18